Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

This publication has 25 references indexed in Scilit:

• Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
  Journal of Clinical Oncology, 1999
• Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
  The Lancet, 1997
• Improving the Quality of Reporting of Randomized Controlled Trials
  JAMA, 1996
• The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view
  Critical Reviews in Oncology/Hematology, 1995
• Selection of large and objectively measurable target lesions in EORTC phase II trials: Impact on recruitment and response rate
  European Journal Of Cancer, 1993
• Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma
  European Journal of Cancer and Clinical Oncology, 1990
• Quality control of validity of data collected in clinical trials
  European Journal of Cancer and Clinical Oncology, 1989
• Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group
  European Journal of Cancer and Clinical Oncology, 1987
• Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas
  European Journal of Cancer and Clinical Oncology, 1987
• Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma
  Cancer Chemotherapy and Pharmacology, 1986